The management of ulcerative colitis

S. B. Hanauer*, F. J. Baert

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


The treatment of ulcerative colitis (UC) remains empiric because of undetermined etiology and pathogenesis and incomplete understanding of the underlying immunoinflammatory events. However, considerable progress has been made in the management of this disease with the availability and wider use of newer aminosalicylates and immunomodulating agents. The clinician confronted with a patient with chronic ulcerative colitis must weigh the advantages of continued medical therapy against the potential curability with improved surgical techniques. After a brief discussion of the current classes of medicines and their pathophysiological basis of action, we focus on standard approaches to the different clinical syndromes and their complications.

Original languageEnglish (US)
Pages (from-to)497-505
Number of pages9
JournalAnnual Review of Medicine
StatePublished - Jan 1 1995


  • Corticosteroids
  • Cyclosporin
  • Immunosuppressive
  • Inflammatory bowel disease
  • Mesalamine

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Fingerprint Dive into the research topics of 'The management of ulcerative colitis'. Together they form a unique fingerprint.

Cite this